GlobalData analysts predicts that the myostatin inhibitor drug class will be a key driver of growth within the SMA market in years to come.
Share prices dropped last week after a key asset from Novartis’ $12bn Avidity deal fumbled in a Phase III trial.
Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.
Investigators performed a meta-analysis of the ORACLE2 dataset, reviewing pooled data from 6,513 control-arm participants, aged 12 years and above, from 22 clinical trials.
Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201.
Biotechs and investors are increasingly altering their strategies amid changes in the development and commercial landscape.
